Chemo shot straight into tumor could cut side effects
NCT ID NCT07495098
First seen Apr 06, 2026 · Last updated Jun 22, 2026 · Updated 10 times
Summary
This early-stage trial tests injecting the chemotherapy drug cisplatin directly into lung tumors using a thin tube with a camera. The goal is to see if this approach is safe and can kill more cancer cells while causing fewer side effects than standard IV chemo. The study will enroll 12 adults with stage IV non-small cell lung cancer.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LUNG CANCER METASTATIC are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
cisplatin
What this could lead to
If it works, this could point toward a less toxic way to deliver chemotherapy directly into lung tumors, potentially improving treatment outcomes with fewer side effects.
What could go wrong
This is a very early Phase 1 trial with only 12 participants, so safety and dosing are still being tested. It may not work as hoped, and there are risks from the procedure itself, such as bleeding or infection.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.